Current Edition


Bluebird Bio has ‘doubts’ about continuing to do business through 2022, announces CFO resignation

With two of its prized gene therapies on clinical hold and another, Zynteglo, pulled from the market in Europe seven months ago after it was …

Continue Reading →

With the pricing situation ‘untenable’ in Europe, Bluebird will wind down its operations in the ‘broken’ market

Unable to reach a consensus with authorities in Europe around fair gene therapy pricing, bluebird bio will “wind down” its operations there to focus on …

Continue Reading →